At Dr. David Macklin's weight management practice in Toronto, the name Ozempic is mentioned almost daily in appointments. But recently, another word is coming up just as often — generics.
"It is a regular conversation, daily in fact, where patients will be asking when their … medications may be less expensive," said Macklin, who is the director of the Medcan Weight Management Program.
Novo Nordisk — the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy — had for years held a patent on semaglutide, the active ingredient in those drugs that triggers the release of insulin and is used to treat diabetes and to aid weight loss.
Its regulatory exclusivity kept costs high because Novo Nordisk was the only company that could make the drugs. According to Macklin, a monthly supply of Ozempic or Wegovy costs between $300 and $400 — sometimes even more depending on the dose.
But Novo Nordisk's patent expired in Canada some time ago and its exclusive market protection expired in January .…